Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.

Product Highlight - QTERN

29 Nov 2019
• Superior HbA1c reduction vs DPP4i +Met or SGLT2i +Met1

• Nearly 2x patients achieved HbA1c <7%1

• Established safety profile of DPP4i with additional benefits of SGLT2i3,5-8

• Extends oral therapy with a once daily tablet4-7



References:
1. Rostenstock J, et al. Diabetes Care 2015; 38(3):376·383.
2. T. Vilsboll, et al. Dapagliflozin plus Saxagliptin shows noninferior HbA1c reductions vs insulin Glargine in patients with Type 2 Diabetes Inadequately.
3. Qtern Malaysia Prescribing Information, AstraZeneca, 2019.
4. Lokhandwala T, et al. J Med Econ. 2016: 19: 203-12.
5. Del Prato S, et al. Diabetes Obes Metab 2018; 20: 1542·1546.
6. Matthaei S, et al. Diabetes Care. 2015: 38: 2018-2024.
7. Bailey CJ, et aI. Lancet 2010; 37: 2233-33.
8. Del Prato S, et al. Diabetes Obes Metab 2015;17: 581-90.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.